Pharm Exec profiles its 2022 Emerging Pharma Leaders.
Click on the links below to read the profiles of Pharm Exec's 2022 Emerging Pharma Leaders.
Naveen Bazaj, Head of Corporate Development, Alector
Gardner Gendron, Chief/US Head of Commercial, NS Pharma
Aida Habtezion, MD, Senior VP, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer
Matthew J. Hawryluk, PhD, Executive VP, Chief Business Officer and Cambridge Site Head, Gritstone bio
Charmaine Lykins, Chief Commercial Officer, Karuna Therapeutics
Divya Chadha Manek, Senior Vice President of Clinical Development, Eyebiotech Limited (EyeBio)
Susan Pandya, MD, Vice President, Clinical Development, and Head of Cancer Metabolism Global Development Oncology and Immuno-Oncology, Servier Pharmaceuticals
Matthew R. Price, Co-Founder, Executive Vice President, Chief Operating Officer, and Board Director, Promontory Therapeutics
Quiona Russell, PhD, Associate Director of Medical Information and Medical Communication, G1 Therapeutics
Patricia Torr, US President and General Manager, Idorsia Pharmaceuticals
Shetal Vyas, Vice President of Operations, Ferring Pharmaceuticals
*From a pool of nominations, these final selections were judged in a blinded process by three Pharmaceutical Executive Editorial Advisory Board members and a former EPL. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.